Trial ID or NCT#

NCT02465060

Status

not recruiting iconNOT RECRUITING

Purpose

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Official Title

Molecular Analysis for Therapy Choice (MATCH)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

James Ford
James Ford
Medical oncologist, Gastrointestinal specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

Contact us to find out if this trial is right for you.

CONTACT

Anastasia L Harper
650-725-0378